# US 2020/0390786 A1 · Compositions and methods for treating ovarian tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390786 A1
- Document ID: US20200390786A1
- Status: Published application
- Kind: A1
- Application number: 16/499,393
- Filed: 2018-03-30
- Published: 2020-12-17
- Earliest claimed: 2017-03-31
- Assignees: Dana-Farber Cancer Institute, Inc.; The Broad Institute, Inc.; Massachusetts Institute of Technology
- Applicants: Dana-Farber Cancer Institute, Inc.; The Broad Institute, Inc.; Massachusetts Institute of Technology
- Inventors: Levi Garraway; Benjamin Izar; Aviv Regev; Orit Rozenblatt-Rosen; Asaf Rotem; Elizabeth Stover; Itay Tirosh
- Web page: https://patentgrep.com/patent/US20200390786A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61P 35/00: Antineoplastic agents
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/28: Compounds containing heavy metals
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 33/243: Platinum; Compounds thereof
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/39533: {against materials from animals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.

## Claims

### Claim 1

A method for treating or preventing a gynecological tumor in a subject comprising:
identifying a subject with a gynecological tumor; and
administering to the subject a therapeutically effective amount of a signal transducer and activator of transcription 3 (STAT3) activity inhibitor,
thereby treating or preventing the gynecological tumor in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gynecological tumor comprises an ovarian tumor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is identified as having elevated STAT3 activity, or wherein the subject is identified as in need of inhibiting STAT3 activity.

### Claim 4 (depends on 1)

The method of claim 1, wherein the STAT3 activity inhibitor is administered intraperitoneally.

### Claim 5 (depends on 1)

The method of claim 1, wherein the STAT3 activity is selected from the group consisting of STAT3 phosphorylation, STAT3 dimerization, STAT3 binding to a polynucleotide comprising a STAT3 binding site, STAT3 binding to genomic DNA, activation of a STAT3 responsive gene and STAT3 nuclear translocation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the STAT3 inhibitor comprises pyrimethamine, atovaquone, pimozide, guanabenz acetate, alprenolol hydrochloride, nifuroxazide, solanine alpha, fluoxetine hydrochloride, ifosfamide, pyrvinium pamoate, moricizine hydrochloride, 3,3′-oxybis[tetrahydrothiophene, 1,1,1′,1′-tetraoxide], 3-(1,3-benzodioxol-5-yl)-1,6-dimethyl-pyrimido[5,4-e]-1,2,4-triazine-5,7(-1H,6H)-dione, 2-(1,8-Naphthyridin-2-yl)phenol, 3-(2-hydroxyphenyl)-3-phenyl-N,N-dipropylpropanamide as well as any derivatives of these compounds or analogues thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the STAT3 activity inhibitor comprises JSI-124 (cucurbitacin I).

### Claim 8 (depends on 7)

The method of claim 7, wherein the JSI-124 (cucurbitacin I) is administered at a dose of about 0.1 μM.

### Claim 9 (depends on 7)

The method of claim 7, wherein tumor cell growth in the subject's abdomen is inhibited.

### Claim 10 (depends on 7)

The method of claim 7, wherein subcutaneous tumor cell growth in the subject is inhibited.

### Claim 11 (depends on 7)

The method of claim 7, wherein ovarian tumor cell metastases in the subject are inhibited.

### Claim 12 (depends on 7)

The method of claim 7, wherein malignant abdominal fluid (ascites) is inhibited.

### Claim 13 (depends on 7)

The method of claim 7, wherein tumor recurrence is prevented.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering a therapeutically effective amount of a chemotherapeutic agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the chemotherapeutic agent comprises a platinum-based chemotherapeutic agent or a taxane-based chemotherapeutic agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the platinum-based chemotherapeutic agent comprises cisplatin or carboplatin.

### Claim 17 (depends on 14)

The method of claim 14, wherein the chemotherapeutic agent is administered prior to, simultaneously with, or subsequent to administration of the STAT3 activity inhibitor.

### Claim 18 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 19 (depends on 1)

The method of claim 1, wherein the subject has received prior treatment for the gynecological tumor.

### Claim 20 (depends on 1)

The method of claim 1, wherein the gynecological tumor is resistant to platinum-based chemotherapy.

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject has minimal residual disease (MRD) following platinum-based chemotherapy.

### Claim 22

A method for treating a gynecological tumor in a subject comprising:
identifying a subject with a gynecological tumor;
administering to the subject a therapeutically effective amount of a chemotherapeutic agent to inhibit the gynecological tumor; and
administering to the subject a therapeutically effective amount of a STAT3 activity inhibitor to prevent recurrence of the gynecological tumor and development of metastases, thereby treating or preventing the gynecological tumor in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the STAT3 activity inhibitor is administered at least one month after administration of the chemotherapeutic agent.

### Claim 24

A method for treating a platinum-resistant gynecological tumor in a subject comprising:
identifying a subject with a platinum-resistant gynecological tumor;
administering to the subject a therapeutically effective amount of a STAT3 activity inhibitor;
administering to the subject a therapeutically effective amount of a chemotherapeutic agent, thereby treating the platinum-resistant gynecological tumor in the subject.

### Claim 25 (depends on 19)

The method of claim 19, wherein the STAT3 activity inhibitor is administered prior to the chemotherapeutic agent.

### Claim 26

A method of treating platinum-based chemotherapy resistant ovarian cancer comprising treating a subject in need thereof with an inhibitor of the JAK/STAT pathway.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the subject has minimal residue disease (MRD) or the ovarian cancer is a relapse.

### Claim 28 (depends on 26, 27)

The method according to claim 26 or 27, wherein the inhibitor is JSI-124.

### Claim 29

A method of treating ovarian cancer comprising treating a subject in need thereof with an agent capable of inhibiting expression or activity of one or more genes or polypeptides selected from the group consisting of JAK1, STAT3, STAT2, STAT1, OSMR, STAT6, RELA, ERBB2, GF1R, ERBB3, IL10RB, FGFR1, CXCR4, CXCL2, CXCL10, CXCL11, HLA-DRA, HLA-DRB1, HLA-DQB1, IDO1, MYBL2 and FGF13.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the ovarian cancer is chemotherapy resistant.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the ovarian cancer is platinum-based chemotherapy resistant.

### Claim 32 (depends on 29, 30, 31)

The method according to any of claims 29 to 31, wherein said agent comprises a therapeutic antibody, bi-specific antibody, antibody fragment, antibody-like protein scaffold, aptamer, genetic modifying agent or small molecule.

### Claim 33 (depends on 29, 30, 31, 32)

The method according to any of claims 29 to 32, wherein the gene or polypeptide is a surface or secreted gene.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the agent targets a secreted protein or a receptor for the secreted protein.

### Claim 35 (depends on 33)

The method according to claim 33, wherein the agent targets a ligand for a surface receptor.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 29 to 35, further comprising administering platinum-based chemotherapy.

### Claim 37

A method of predicting a response to platinum-based chemotherapy in a subject suffering from ovarian cancer comprising detecting in a tumor sample obtained from the subject expression of one or more genes selected from the group consisting of JAK1, STAT3, STAT2, STAT1, OSMR, STAT6, RELA, ERBB2, GF1R, ERBB3, IL10RB, FGFR1, CXCR4, CXCL2, CXCL10, CXCL11, HLA-DRA, HLA-DRB1, HLA-DQB1, IDO1, MYBL2 and FGF13, wherein high expression in the tumor sample indicates a weak response to platinum-based chemotherapy and low expression indicates a strong response to platinum-based chemotherapy.

### Claim 38

A method of detecting ovarian cancer stem cells in a tumor sample obtained from a subject suffering from ovarian cancer comprising detecting expression of a gene signature comprising one or more genes selected from the group consisting of ALDH1A3, CD24, CD133, FN1, ACTA2, MYL9, GAS6, IGFBP5, FGFR1, CALD1, CFI, CRB2, PRDX4, IGFBP6 and RPS20.

### Claim 39

A method of treating ovarian cancer comprising treating a subject in need thereof with an agent capable of targeting ovarian cancer stem cells characterized by a gene signature comprising one or more genes selected from the group consisting of ALDH1A3, CD24, CD133, FN1, ACTA2, MYL9, GAS6, IGFBP5, FGFR1, CALD1, CFI, CRB2, PRDX4, IGFBP6 and RPS20.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the agent targets a surface protein on the ovarian cancer stem cells.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the agent comprises a therapeutic antibody, bispecific antibody, antibody fragment, antibody-like protein scaffold, aptamer or CAR T cell.

### Claim 42 (depends on 39, 40, 41)

The method according to any of claims 39 to 41, further comprising administering platinum-based chemotherapy.

### Claim 43 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 39, 40, 41)

The method of treatment according to any of claims 26 to 35 or 39 to 41, wherein the treatment is administered as an adjuvant or neoadjuvant therapy.

### Claim 44 (depends on 1)

The method of claim 1, wherein the inhibitor comprises a therapeutic antibody, bi-specific antibody, antibody fragment, antibody-like protein scaffold, aptamer, genetic modifying agent or small molecule.
